Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 107676004 | 10767600 | 4 | F | 2015 | 20160720 | 20150205 | 20160728 | EXP | CA-ABBVIE-15K-028-1341450-00 | ABBVIE | 0.00 | M | Y | 75.36000 | KG | 20160728 | CN | COUNTRY NOT SPECIFIED | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 107676004 | 10767600 | 1 | PS | HUMIRA | ADALIMUMAB | 1 | Subcutaneous | Y | U | 6047099,6051290 | 125057 | 40 | MG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | QOW | ||||
| 107676004 | 10767600 | 2 | SS | HUMIRA | ADALIMUMAB | 1 | Subcutaneous | Y | U | 6047099,6051290 | 125057 | 40 | MG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | QOW | ||||
| 107676004 | 10767600 | 3 | SS | HUMIRA | ADALIMUMAB | 1 | Subcutaneous | Y | U | 6047099,6051290 | 125057 | 40 | MG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | /wk | ||||
| 107676004 | 10767600 | 4 | C | METHOTREXATE. | METHOTREXATE | 1 | Intravenous (not otherwise specified) | 0 | 25 | MG | /wk | ||||||||
| 107676004 | 10767600 | 5 | C | CITALOPRAM | CITALOPRAM HYDROBROMIDE | 1 | Oral | 0 | 40 | MG | QD | ||||||||
| 107676004 | 10767600 | 6 | C | CITALOPRAM | CITALOPRAM HYDROBROMIDE | 1 | 0 | ||||||||||||
| 107676004 | 10767600 | 7 | C | BUPROPION. | BUPROPION | 1 | Oral | 0 | 150 | MG | QD | ||||||||
| 107676004 | 10767600 | 8 | C | BUPROPION. | BUPROPION | 1 | 0 | ||||||||||||
| 107676004 | 10767600 | 9 | C | CLONAZEPAM. | CLONAZEPAM | 1 | Oral | 1 OR 2 MG | 0 | QD | |||||||||
| 107676004 | 10767600 | 10 | C | ZOPICLONE | ZOPICLONE | 1 | Oral | 0 | 15 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 107676004 | 10767600 | 1 | Crohn's disease |
| 107676004 | 10767600 | 4 | Crohn's disease |
| 107676004 | 10767600 | 5 | Mental disorder |
| 107676004 | 10767600 | 6 | Antidepressant therapy |
| 107676004 | 10767600 | 7 | Mental disorder |
| 107676004 | 10767600 | 8 | Antidepressant therapy |
| 107676004 | 10767600 | 9 | Panic attack |
| 107676004 | 10767600 | 10 | Mental disorder |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 107676004 | 10767600 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 107676004 | 10767600 | Abdominal adhesions | |
| 107676004 | 10767600 | Anastomotic ulcer | |
| 107676004 | 10767600 | Crohn's disease | |
| 107676004 | 10767600 | Drug ineffective | |
| 107676004 | 10767600 | Infection | |
| 107676004 | 10767600 | Intestinal obstruction | |
| 107676004 | 10767600 | Intestinal stenosis | |
| 107676004 | 10767600 | Myalgia | |
| 107676004 | 10767600 | Post-traumatic stress disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 107676004 | 10767600 | 1 | 20090204 | 2013 | 0 | |
| 107676004 | 10767600 | 2 | 2013 | 2015 | 0 | |
| 107676004 | 10767600 | 3 | 2015 | 0 | ||
| 107676004 | 10767600 | 4 | 2009 | 0 | ||
| 107676004 | 10767600 | 5 | 2011 | 0 | ||
| 107676004 | 10767600 | 7 | 2012 | 0 | ||
| 107676004 | 10767600 | 9 | 2011 | 0 |